Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Idorn

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
BMC Nephrology|July 28, 2012
Anti-glomerular basement membrane glomerulonephritis and thrombotic microangiopathy in first degree relatives: a case reportThomas Idorn, Lone Schejbel, Casper Rydahl, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|September 22, 2012
Plasma adiponectin before and after kidney transplantationThomas Idorn, Mads Hornum, Mette Bjerre, et al.
Circulation|December 20, 2018
Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney DiseaseJohannes F E Mann, Vivian Fonseca, Ofri Mosenzon, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 6, 2020
Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney DiseaseJohannes F E Mann, Vivian A Fonseca, Neil R Poulter, et al.
Circulation|May 29, 2019
Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial"Johannes F E Mann, Vivian Fonseca, Ofri Mosenzon, et al.
The Lancet. Diabetes & Endocrinology|September 24, 2020
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trialsJohannes F E Mann, Thomas Hansen, Thomas Idorn, et al.
Neurogastroenterology and Motility|January 23, 2019
Gastrointestinal motility in patients with end-stage renal disease on chronic hemodialysisBo Broberg, Jan L Madsen, Stefan Fuglsang, et al.
Pituitary|January 7, 2023
Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysisNanna Thurmann Jørgensen, Trine Møller Erichsen, Morten Buus Jørgensen, et al.
Diabetes, Obesity & Metabolism|May 19, 2021
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysisJohannes F E Mann, John B Buse, Thomas Idorn, et al.
Diabetes Care|August 19, 2015
Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized TrialThomas Idorn, Filip K Knop, Morten B Jørgensen, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
BMC Nephrology|July 28, 2012
Anti-glomerular basement membrane glomerulonephritis and thrombotic microangiopathy in first degree relatives: a case reportThomas Idorn, Lone Schejbel, Casper Rydahl, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|September 22, 2012
Plasma adiponectin before and after kidney transplantationThomas Idorn, Mads Hornum, Mette Bjerre, et al.
Circulation|December 20, 2018
Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney DiseaseJohannes F E Mann, Vivian Fonseca, Ofri Mosenzon, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 6, 2020
Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney DiseaseJohannes F E Mann, Vivian A Fonseca, Neil R Poulter, et al.
Circulation|May 29, 2019
Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial"Johannes F E Mann, Vivian Fonseca, Ofri Mosenzon, et al.
The Lancet. Diabetes & Endocrinology|September 24, 2020
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trialsJohannes F E Mann, Thomas Hansen, Thomas Idorn, et al.
Neurogastroenterology and Motility|January 23, 2019
Gastrointestinal motility in patients with end-stage renal disease on chronic hemodialysisBo Broberg, Jan L Madsen, Stefan Fuglsang, et al.
Pituitary|January 7, 2023
Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysisNanna Thurmann Jørgensen, Trine Møller Erichsen, Morten Buus Jørgensen, et al.
Diabetes, Obesity & Metabolism|May 19, 2021
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysisJohannes F E Mann, John B Buse, Thomas Idorn, et al.
Diabetes Care|August 19, 2015
Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized TrialThomas Idorn, Filip K Knop, Morten B Jørgensen, et al.
Pageof 4